BioNTech Settles Lawsuit with UPenn for $467 Million
BioNTech agrees to pay $467 million to the University of Pennsylvania, resolving a legal dispute. Learn more about this significant pharmaceutical settlement.
Topic
pharmaceuticals
A collection of 34 issues
BioNTech Settles Vaccine Royalty Disputes with NIH and UPenn
BioNTech reaches settlements with NIH and University of Pennsylvania over COVID-19 vaccine royalties, marking a significant legal resolution in healthcare.
Salesforce Enters Pharmaceutical CRM Market, Shaking Up Competition
Explore the competitive dynamics in the pharmaceutical CRM market as Salesforce ventures into the space, transforming market dynamics and strategies.
Brookline Rates Medicus Pharma as Buy with $12 Target
Brookline Capital initiates coverage of Medicus Pharma, assigning a Buy rating and targeting $12, highlighting its innovative skin patch technology.
Novo Shares Plummet 21%, Wiping Out $100 Billion
Novo's U.S.-listed shares see a dramatic 21% drop, erasing over $100 billion in market value. Discover the impact on the pharmaceutical giant.
Retail Investors Flood Novo Nordisk Despite Obesity Drug Setback
U.S. retail investors dramatically increase fund flows into Novo Nordisk, with a 32-fold surge following disappointing obesity drug data. Discover the market reaction.
Eli Lilly Shares Surge Post-FDA Approval for Zepbound
Eli Lilly's stock soared following FDA approval of Zepbound, a novel weight-loss treatment for sleep apnea, boosting its position in the healthcare sector.
Eli Lilly Rises 1.6% While ResMed Falls 4% in Monday Trading
Eli Lilly experiences a 1.6% midday rise, boasting a 34% year-to-date gain, while ResMed sees a 4% decline, affecting stock market trends in pharmaceuticals and medical devices.
Lilly Boosts Weight-Loss Market Position with Zepbound Approval
Eli Lilly strengthens its weight-loss market position with the approval of Zepbound, complementing its existing drug, Mounjaro. Discover more about Lilly's strategic expansion.
FDA Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea
Eli Lilly's Zepbound receives FDA approval for treating obstructive sleep apnea in obese adults, marking a significant advancement in pharmaceutical care.